TITLE

Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof

AUTHOR(S)
Fisman, Enrique Z.; Motro, Michael; Tenenbaum, Alexander
PUB. DATE
January 2003
SOURCE
Cardiovascular Diabetology;2003, Vol. 2, p11
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The impressive correlation between cardiovascular disease and glucose metabolism alterations has raised the likelihood that atherosclerosis and type 2 diabetes may share common antecedents. Inflammation is emerging as a conceivable etiologic mechanism for both. Interleukins are regulatory proteins with ability to accelerate or inhibit inflammatory processes. Presentation of the hypothesis: A novel interleukins classification is described, based on their role in diabetes and atherosclerosis, hypothesizing that each interleukin (IL) acts on both diseases in the same direction — regardless if harmful, favorable or neutral. Testing the hypothesis: The 29 known interleukins were clustered into three groups: noxious (the "bad", 8 members), comprising IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-17 and IL-18; protective (the "good", 5 members), comprising IL-4, IL-10, IL-11, IL-12 and IL-13; and "aloof", comprising IL-5, IL-9, IL-14, IL-16 and IL-19 through IL-29 (15 members). Each group presented converging effects on both diseases. IL-3 was reluctant to clustering. Implications: These observations imply that 1) favorable effects of a given IL on either diabetes or atherosclerosis predicts similar effects on the other; 2) equally, harmful IL effects on one disease can be extrapolated to the other; and 3) absence of influence of a given IL on one of these diseases forecasts lack of effects on the other. These facts further support the unifying etiologic theory of both ailments, emphasizing the importance of a cardiovascular diabetologic approach to interleukins for future research. Pharmacologic targeting of these cytokines might provide an effective means to simultaneously control both atherosclerosis and diabetes.
ACCESSION #
28683658

 

Related Articles

  • Cytokines and atherosclerosis: a comprehensive review of studies in mice. Kleemann, Robert; Zadelaar, Susanne; Kooistra, Teake // Cardiovascular Research;Aug2008, Vol. 79 Issue 3, p360 

    In the past few years, inflammation has emerged as a major driving force of atherosclerotic lesion development. It is now well-established that from early lesion to vulnerable plaque formation, numerous cellular and molecular inflammatory components participate in the disease process. The most...

  • Paradoxes and Pitfalls of Interleukin-33 in Atherosclerosis. Kunes, Pavel; Holubcova, Zdenka; Kolackova, Martina; Krejsek, Jan // Open Clinical Chemistry Journal;2012, Vol. 5, p13 

    Atherosclerosis is definitely considered as an inflammatory/immunopathological disease. The long-standing low-grade inflammation is focused on the components of the vessel wall. Initially, this inflammation was assumed to be driven by the pro-inflammatory Th1 cellular and cytokine immune...

  • Interleukin-18: a potent pro-inflammatory cytokine in atherosclerosis. Badimon, Lina // Cardiovascular Research;Nov2012, Vol. 96 Issue 2, p172 

    No abstract available.

  • Atherogenic Effect of Interleukin-2 and Antiatherogenic Effect of Interleukin-2 Antibody in Apo-E-Deficient Mice. Upadhya, Subramanya; Mooteri, Sahantalaxmi; Peckham, Norman; Pai, Ramdas G. // Angiology;May/Jun2004, Vol. 55 Issue 3, p289 

    Growing evidence suggests that atherosclerosis is an immune-mediated inflammatory process and that cytokines participate as mediators in this process. Of the cytokines, interleukins, which are released from both immune and nonimmune cells of vascular wall, are found to have multiple effects....

  • Correlative association of interleukin-6 with intima media thickness: a meta-analysis. Bo Zhang; Jing Wang; Yong Xu; Xiao Zhou; Junsong Liu; Jing Xu; Bo Li; Guang Zhi // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 3, p4731 

    Background: Involvement of inflammatory processes in the atherogenesis is now well-recognized. The present study examines the relationship between a proinflammatory cytokine, interleukin-6 (IL-6), and atherosclerosis by meta-analyzing the correlation coefficients between IL-6 and intima media...

  • Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Vickers, Mark A.; Green, Fiona R.; Terry, Catherine; Mayosi, Bongani M.; Julier, Cecile; Lathrop, Mark; Ratcliffe, Peter J.; Watkins, Hugh C.; Keavney, Bernard // Cardiovascular Research;Mar2002, Vol. 53 Issue 4, p1029 

    Objective: Baseline concentrations of plasma C-reactive protein (CRP) are associated with coronary heart disease. Interleukin-6 (IL-6) regulates CRP gene expression; a promoter polymorphism (–174G/C) of the IL-6 gene has been shown to influence IL-6 transcription but the...

  • IL-12 concentrations in the aqueous humor and serum of diabetic retinopathy patients. Gverović Antunica, Antonela; Karaman, Ksenija; Znaor, Ljubo; Sapunar, Ada; Buško, Vesna; Puzović, Velibor // Graefe's Archive of Clinical & Experimental Ophthalmology;Jun2012, Vol. 250 Issue 6, p815 

    Background: Previous studies suggest that inflammation plays an important part in the pathogenesis of diabetes. Cytokines may have a role in both positive and negative control of immunological reactions. Among many cytokines, interleukin 12 (IL-12) is known to be a strong pro-inflammatory...

  • Uremia-associated immune defect: The IL-10–CRP axis. Girndt, Matthias; Ulrich, Christof; Kaul, Harald; Sester, Urban; Sester, Martina; Köhler, Hans // Kidney International Supplement;May2003, Issue 84, p76 

    Uremia-associated immune defect: The IL-10–CRP axis. Unstable atherosclerotic disease is related to systemic inflammation. While this inflammation remains at a subclinical level in otherwise healthy individuals, chronic elevation of pro-inflammatory cytokines is a common feature in...

  • Do inflammatory cytokine genes confer susceptibility to diabetic nephropathy? Maeda, Shiro // Kidney International;Aug2008, Vol. 74 Issue 4, p413 

    Microinflammation has been recognized as an important process for the progression of diabetic nephropathy. Inflammatory cytokines, such as interleukin-6 produced by infiltrating cells or renal cells, play important roles in the pathogenesis of diabetic nephropathy. Although the mechanisms...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics